While these preclinical data nominate TP53 status as a potential biomarker of sensitivity to ATM-directed radiosensitization strategies, it is unknown whether PTEN-altered brainstem gliomas are likely to respond to ATM inactivation in this manner. This evidence concerns the gene TP53 and brain stem glioma.